Holen Sie sich die Stockscreener-App
29.15
0.28%
0.08
Handel nachbörslich:
29.18
0.03
+0.10%
Schlusskurs vom Vortag:
$29.07
Offen:
$28.9
24-Stunden-Volumen:
10,013
Relative Volume:
0.63
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-4.21%
1M Leistung:
-5.60%
6M Leistung:
-9.43%
1J Leistung:
+0.38%
1-Tages-Spanne:
$28.90
$29.52
1-Wochen-Bereich:
$28.81
$30.75
52-Wochen-Spanne:
$28.81
$36.03
Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Company Profile
Firmenname
Tema Etf Trust Tema Obesity Cardiometabolic Etf
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie HRTS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRTS
Tema Etf Trust Tema Obesity Cardiometabolic Etf
|
29.15 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
293.28 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
591.15 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
593.33 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
242.75 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
518.66 | 124.43B | 0 | 0 | 0 | 0.00 |
Tema Etf Trust Tema Obesity Cardiometabolic Etf Aktie (HRTS) Neueste Nachrichten
7 Best-Performing Biotech ETFs for December 2024 - NerdWallet
Disruptive Theme of the Week: Happy Post-Election Themes - ETF Trends
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win - Yahoo Finance
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
(HRTS) Proactive Strategies - Stock Traders Daily
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' - Benzinga
Tap the Weight-Loss Drug Market With These ETFs - Yahoo Finance
Tema Endowment ETF plans to ride Wall Street’s private-asset craze - Pensions & Investments
Stone Ridge 2060 Inflation Protected Longevity Income ETF (LIAU) Chart and Price History 2024 - MarketBeat
An Endowment ETF Plans to Ride Wall Street’s Private-Asset Craze - Bloomberg
Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Shares Up 0.1% - Defense World
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says - CNBC
HRTS: Generating Alpha In Obesity Treatment (NASDAQ:HRTS) - Seeking Alpha
Disruptive Theme of the Week: The Rise of Active Thematic ETFs - ETF Trends
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment - Yahoo Finance
HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside - Seeking Alpha
ETF Innovators: 11 people disrupting the industry, creating unique products, and delivering mammoth returns - Business Insider
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - Benzinga
This ETF is trying to satisfy appetites for weight loss stocks - CNBC
ETF IQ: Mutual Fund Managers Have the Luxury to Just Say 'No' - Bloomberg
ETF IQ: Mutual Fund Managers Have the Luxury to Just Say ‘No’ - Bloomberg
Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Stock Price Down 1.1% - Defense World
Weight-loss drug forecasts jump to $150 billion as supply grows - The Business Standard
Watch Looking at Next Gen of Weight Loss: Tema ETFs CEO - Bloomberg
Spot Ether ETF: a Crypto Game Changer? - Opto RoW
ETFs to Profit from the Weight Loss Drug Boom - Yahoo Finance
OZEM, Weight Loss Drug ETFs: Should You Invest? - etf.com
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters - BioSpace
Play These New ETFs to Tap Lucrative Weight Loss Drug Market - Yahoo Finance
Another thematic ETF launches to target global obesity battle - InvestmentNews
Thematic ETF Winners of the Q1 2024 Earnings Season - ETF Trends
S&P 500: April Selloff Could Be a Very Good Thing for the Months Ahead - Investing.com
IBD Stock Of The Day Pops After Obesity Drug Crushes Sales Views - Investor's Business Daily
The 5 Best Biotech ETFs of 2024 - etf.com
Webcast: How to Invest in the Weight Loss Drug Revolution - ETF Trends
This weight-loss ETF has performed well. Here’s a look at other options. - MarketWatch
Healthcare ETFs for the Weight-Loss Drug Boom & Beyond - Yahoo Finance
Is the global battle against obesity an opportunity for investors? - InvestmentNews
First Weight Loss ETF from Tema ETFs Announces Name Change, Tops $50 Million AUM - Markets Insider
'Continued innovation' is key when investing in weight loss trend - Yahoo Finance
The Truth HRTSETF Focus on TheStreet: ETF research and Trade Ideas - TheStreet
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade - MarketWatch
New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype - BNN Bloomberg
Be Thankful — It Could Have Been So Much Worse - Bloomberg
Finanzdaten der Tema Etf Trust Tema Obesity Cardiometabolic Etf-Aktie (HRTS)
Es liegen keine Finanzdaten für Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.17%
0.28%
Kapitalisierung:
|
Volumen (24h):